Results 201 to 210 of about 182,908 (236)

Apolipoprotein A-I inhibited group II innate lymphoid cell response mediated by microRNA-155 in allergic rhinitis. [PDF]

J Allergy Clin Immunol Glob
Zeng Y, Zeng Q, Wen Y, Li J, Xiao H, Yang C, Luo R, Liu W.   +7 more
europepmc   +1 more source

Long‐Term Effect of Allergen Immunotherapy in Responder Local Allergic Rhinitis Patients: Symptom Control, and Prevention of Asthma and Allergic Sensitizations

Allergy, EarlyView.
LAR patients who respond to AIT during the first year and are treated for two more years continue improving (less symptoms and medication intake) during the following seven years. AIT prevents the onset of asthma and allergic sensitizations in responder LAR individuals during the seven years following discontinuation.
Almudena Testera‐Montes, Laura Zubiaga‐Fernandez, Carlos J. Aranda, Irene Garcia‐Esteban, Trinidad Ilda Gaitan‐Nievas, Dulce Sanchez‐Torralvo, Cristobalina Mayorga, Maria J. Torres, Ibon Eguiluz‐Gracia, Carmen Rondon   +9 more
wiley   +1 more source

Sequence of Immunological Events During IgE‐Mediated Allergic Reactions to Food

Allergy, EarlyView.
ABSTRACT Food allergies (FA) represent a significant global health burden. Upon allergen re‐exposure, allergic patients exhibit a sequence of symptoms that vary in terms of affected organ systems, severity, time of onset and allergen reactivity thresholds.
N. A. Nagy, D. Schnoegl, V. Houghton, L. O'Mahony, A. F. Santos, E. F. Knol, A. Kuehn, T. Eiwegger   +7 more
wiley   +1 more source

Characterization of Human Group 9 Innate Lymphoid Cells in Response to Allergen Immunotherapy in Patients With Allergic Rhinitis

Allergy, EarlyView.
We aimed to report the existence and profile of group 9 innate lymphoid cells (ILC9s). Overall, ILC9 proportions in AR patients show differences compared to healthy subjects and responder SCIT patients. IL‐9 expression decreases after siRNA inhibition of Bach2 suggesting Bach2 could display as a transcription factor of ILC9.
Ya‐Qi Peng, Te Zhang, Xiao‐Qing Liu, Ismail Ogulur, Qi Sun, Beate Ruckert, Bi‐Xin He, De‐Hua Chen, Hideaki Morita, Hui‐Jing Ye, Qing‐Ling Fu, Cezmi A. Akdis   +11 more
wiley   +1 more source

Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice

Allergy, EarlyView.
ABSTRACT Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...
Harold Wilson‐Morkeh, Lior Seluk, Philipp Bosch, Carolina Aguiar, Jens Thiel, Bernhard Hellmich, Michael E. Wechsler, Salman Siddiqui   +7 more
wiley   +1 more source

Blocking group 2 innate lymphoid cell activation and macrophage M2 polarization: potential therapeutic mechanisms in ovalbumin-induced allergic asthma by calycosin. [PDF]

BMC Pharmacol Toxicol
Tian C, Liu Q, Zhang X, Li Z.
europepmc   +1 more source

Allergic Sensitization to Inhalant Allergens in the Upper Respiratory Tract—the B Cell Side

Allergy, EarlyView.
ABSTRACT Allergic diseases are on the rise worldwide, driven by respiratory epithelial barrier dysfunction that promotes sensitization to inhalant allergens such as pollen, dust mites, pet dander, and fungal spores. These antigens trigger IgE‐mediated immune responses that lead to diseases such as allergic rhinitis (AR) and asthma.
Ola Grimsholm, Mohammed Zghaebi, Bita Hambrecht, Tanja Kalic, Christopher C. Udoye, Rudolf Manz, Barbara Bohle, Katarzyna M. Sitnik, Julia Eckl‐Dorna, Heimo Breiteneder   +9 more
wiley   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Comorbid Chronic Rhinosinusitis and Asthma: Shared Risk Factors and Treatment Implications—An EAACI Task Force Report

Allergy, EarlyView.
ABSTRACT Chronic rhinosinusitis (CRS) and asthma are prevalent conditions that often coexist. These diseases share common inflammatory mechanisms, such as T‐helper cell 2 (T2)‐high inflammation, driven by interleukin (IL)‐4, IL‐5, and IL‐13 cytokines.
Sanna Toppila‐Salmi, Sietze Reitsma, Valérie Hox, Simon Gane, Philippe Gevaert, Juan Maza‐Solano, Alma Helevä, Ida Sulku, Kaisa Santala, Iiris Kangasniemi, Ludger Klimek, Adam Chaker, Aspasia Karavelia, Michael Rudenko, Oliver Pfaar, Laura Van Gerven, Shaari Ariana, Michele Schiappoli, Marie Lundberg, Jan Hagemann, Ibon Eguíluz‐Gracia, Andre Moreira   +21 more
wiley   +1 more source

Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema

Allergy, EarlyView.
This study performed an unbiased molecular profiling of CHE patients across diverse etiologies to identify shared pathogenic drivers and evaluate the impact of IL‐4Rα blockade via dupilumab over 16 weeks. CHE shows a mixed immune signature involving type 1, 2, and 3 pathways with features of atopic dermatitis and psoriasis.
Perrine Gery, Rüçhan Ekren, Emilie Bérard, Aurélie Du‐Thanh, Hugo Rimet, Fatma Jendoubi, Vanina Lenief, Nadia Raison‐Peyron, Amel Bouznad, Maria P. Konstantinou, Jonathan Rioual, Lilian Basso, Juliette Mouiren, Manon Boussier, Brigitte Milpied, Cristina Bulai Livideanu, Louise Jaulent, Florence Hacard, Marine A. Lefevre, Audrey Nosbaum, Julien Seneschal, Marc Vocanson, Carle Paul, Nicolas Gaudenzio, Marie Tauber, on behalf of the French Atopic Dermatitis Network from de GREAT Research group   +25 more
wiley   +1 more source